In Leishmaniasis due to Leishmania guyanensis infection, distinct intralesional interleukin-10 and Foxp3 mRNA expression are associated with unresponsiveness to treatment

Journal of Infectious Diseases

Volumn 199, Issue 4, 2009, Pages 576-579

  Bourreau, Eliane ^a   Ronet, Catherine ^c   Darsissac, Edith ^a   Lise, Marie Claire ^a   Marie, Dominique Sainte ^b   Clity, Emmanuel ^b   Tacchini Cottier, Fabienne ^c   Couppie, Pierre ^b   Launois, Pascal ^a,c  

^a INSTITUT PASTEUR DE LA GUYANE   (French Guiana)

^b CENTRE HOSPITALIER DE CAYENNE   (French Guiana)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; MESSENGER RNA; PENTAMIDINE ISETHIONATE; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE DURATION; FEMALE; GENE EXPRESSION; HUMAN; LEISHMANIA; LEISHMANIASIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANIMALS; ANTIPROTOZOAL AGENTS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-10; LEISHMANIA GUYANENSIS; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; PENTAMIDINE; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY; TREATMENT FAILURE;

EID: 61849106472     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/596508     Document Type: Article

References (15)

1. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19:111-26.
2. Murray HW, Delph-Etienne S. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect Immun 2000; 68:288-93.
3. Murray HW, Hariprashad J, Fichtl RE. Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine. Antimicrob Agents Chemother 1993; 37:1504-5.
4. Murray HW, Oca MJ, Granger AM, Schreiber RD. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection: experimental visceral leishmaniasis. J Clin Invest 1989; 83:1253-7.
5. Murray HW, Berman JD, Wright SD. Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony. J Infect Dis 1988; 157:973-8.
6. Laguna F, Lopez-Velez R, Pulido F, et al. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 1999; 13:1063-9.
7. Bourreau E, Prevot G, Gardon J, Pradinaud R, Launois P. High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment. J Infect Dis 2001; 184:1628-30.
8. +- suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2:389-400.
9. Rouse BT, Suvas S. Regulatory cells and infectious agents: detentes cordiale and contraire. J Immunol 2004; 173:2211-5.
10. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-61.
11. +- T cells in skin lesions of patients with cutaneous leishmaniasis exhibit phenotypic and functional characteristics of natural regulatory T cells. J Infect Dis 2006; 193:1313-22.
12. - Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 2007; 204:285-97.
13. - negative T cells as a source of IL-10 in Leishmania major susceptibility. J Immunol 2007; 179:2435-44.
14. +- (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 2007; 204:805-17.
15. Bourreau E, Gardon J, Pradinaud R, et al. Th2 responses predominate during the early phases of infection in patients with localized cutaneous leishmaniasis and precede the development of Th1 responses. Infect Immun 2003; 71:2244-6.